Kerrisdale Capital Announces Latest Short Position, Bavarian Nordic

Kerrisdale Capital has published a report on its latest short position, Danish vaccine manufacturer Bavarian Nordic A/S

. The company's experimental prostate-cancer vaccine, Prostvac-VF, is currently undergoing a Phase III clinical trial. Bavarian Nordic claims that Prostvac has produced "the most pronounced survival to date in prostate cancer," but the Kerrisdale's research indicates that the manufacturer is using misleading comparisons, which do not show real efficacy. Kerrisdale says the Prostac-VF is "ineffective". Kerrisdale Capital's full report on Bavarian Nordic can be found here: http://kerrisdalecap.com/wp-content/uploads/2015/08/BAVA-Report-Kerrisdale-Capital.pdf